Redwood Pharma AB appoints Ulf Björklund as Chief Medical Officer

Redwood Pharma AB (publ), a company that develops pharmaceuticals within ophthalmology, announces today that Ulf Björklund has accepted the company’s offer to become Chief Medical Officer (CMO). In this role, Ulf Björklund will oversee clinical development of the Company’s new product candidate RP101 a therapy to treat chronic Dry Eye Disease in post-menopausal women. The product will be the first to use the IntelliGel® drug delivery platform.

Ulf’s most recent appoint was CEO for Aprea. Ulf brings extensive experience within clinical development and commercialization of pharmaceuticals within Life Science. Among his accomplishments, he has over 22 years of experience at Pharmacia working with clinical development of products including Xalatan, arguably Sweden’s most widely known eye therapy within glaucoma, and over 30 years international experience within pharmaceutical development. Ulf has also had a leading roll in the Swedish Pharmaceutical Society’s program for training in clinical trials.

”Ulf will serve to complement our firm with his unique experience and knowledge within clinical development. He joins Redwood Pharma at an exciting time in the company’s stage of growth. The recruitment of a CMO with Ulf’s background is another significant step in the development of Redwood PHrama and we are very enthusiastic that Ulf has decided to help develop our eye therapies”, says CEO Martin Vidaeus.
 

For more information:
Martin Vidaeus, CEO Redwood Pharma AB (publ.)
Tel: +46 (0) 70 232 29 29
E-mail: martin.vidaeus@redwoodpharma.se
 

About Redwood Pharma
Redwood Pharma develops ophthalmic products for unmet medical needs. The Company’s first project is the development of drug candidate RP101 with a known active substance against chronic dry eye in postmenopausal women who have moderate to severe symptoms. With the drug delivery platform IntelliGel® the release of active substances is controlled. Through the use of IntelliGel®, Redwood Pharma can also improve dosing of other established drugs. Redwood Pharma’s strength lies in formulation and early clinical development. Revenues will be generated through licensing agreements with pharmaceutical companies that have capabilities to manufacture and sell commercial products worldwide.

Redwood Pharma AB (publ.) is listed on AktieTorget, a Swedish Multilateral Trading Facility (Ticker: REDW.ST, ISIN: SE008294789).

For more information see: www.redwoodpharma.com